Recombinant factor VIIa for uncontrollable bleeding in patients with extracorporeal membrane oxygenation: report on 15 cases and literature review by Xavier Repesse et al.
RESEARCH Open Access
Recombinant factor VIIa for uncontrollable
bleeding in patients with extracorporeal
membrane oxygenation: report on 15 cases
and literature review
Xavier Repessé1,3, Siu Ming Au1,3, Nicolas Bréchot1,3, Jean-Louis Trouillet1,3, Pascal Leprince2,3, Jean Chastre1,3,
Alain Combes1,3 and Charles-Edouard Luyt1,3*
Abstract
Introduction: Bleeding is the most frequent complication in patients receiving venoarterial or venovenous
extracorporeal membrane oxygenation (ECMO). Recombinant activated factor VII (rFVIIa) has been used in these
patients with conflicting results. We describe our experience with rFVIIa for refractory bleeding in this setting and
review the cases reported in the literature.
Methods: Clinical characteristics, demographics, bleeding, thrombotic complications, mortality, and rFVIIa
administration were retrospectively collected for analysis from the electronic charts of the 15 patients in our
intensive care unit who received rFVIIa while being given ECMO from January 2006 to March 2011.
Results: Fifteen patients received rFVIIa for persistent bleeding under venoarterial (n = 11) or venovenous (n = 4)
ECMO. Bleeding dramatically decreased in 14 patients, without a major thrombotic event, except in one patient in
whom a major stroke could not be ruled out. Two circuits were changed within the 48 hours after rFVIIa
administration for clots in the membrane and decreased oxygenation but without massive clotting. The mortality
rate was 60%.
Conclusions: rFVIIa use for intractable hemorrhaging in patients receiving ECMO controlled bleeding, without
major thrombotic events, and with 60% dying. Hence, its use warrants discussion, and clinicians should be aware
of the possibility of potentially life-threatening systemic thrombosis, emboli, or circuit clotting. Whether rFVIIa can
save the lives of such patients remains to be determined.
Introduction
Extracorporeal membrane oxygenation (ECMO) may be
used successfully in patients with refractory life-threa-
tening cardiac or respiratory failure [1-3]. Venoarterial
and venovenous extracorporeal devices require anticoa-
gulant therapy to avoid thromboembolic complications,
(for example, circuit thrombosis or pulmonary or sys-
temic emboli) [2,4]. In addition, coagulation-cascade
activation by the circuit and the membrane leads to pla-
telet and coagulation-factor consumption, thereby
increasing the risk of bleeding [5]. Recently, it was sug-
gested that von Willebrand factor abnormalities induced
by extracorporeal circulation could trigger acquired von
Willebrand syndrome and could explain, at least in part,
the elevated bleeding rate in these patients [6]. Indeed,
hemorrhaging represents the most-frequent severe
adverse event in patients receiving extracorporeal circu-
latory or respiratory support, with reported rates up to
30% [2,4]. Recombinant activated factor VII (rFVIIa;
NovoSeven, Novo Nordisk, Copenhagen, Denmark) is a
genetically engineered concentrate of human coagulation
FVII that was originally designed to treat life-threatening
hemorrhages in patients with hemophilia A or B [7]. To
date, on-label indications of rFVIIa are prevention of
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bleeding for surgical interventions or bleeding episodes
in patients with either congenital hemophilia A or B
with antibody inhibitors against standard-factor replace-
ments, or acquired hemophilia, or congenital factor VII
deficiency. In recent years, its off-label use has increased
in cardiac surgery [8-10], liver transplantation [11], or
trauma [12] without affecting mortality rates in those
settings [13,14]. rFVIIa has also been used successfully
in infants and adults receiving ECMO [15,16]. However,
circuit thrombosis, fatal or not, has been described for
ECMO patients given rFVIIa with or without other pro-
thrombotic drugs [17,18]. Because clotting of the circuit
is the second most frequent complication after bleeding,
the use of fVIIa may increase this risk and thus be more
deleterious than beneficial.
Because data are scarce on rFVIIa use in patients with
ECMO, we retrospectively reviewed 15 consecutive
patients administered rFVIIa for life-threatening intract-
able bleeding while receiving ECMO and reviewed all
the cases reported in the literature. Intractable bleeding
was defined as persistent bleeding although all medical
and surgical means to control bleeding have been
exhausted.
Materials and methods
Patient selection and definitions
In our 18-bed tertiary intens ive care unit (ICU), ECMO
is widely used for patients in refractory cardiogenic
shock (venoarterial ECMO) or refractory acute respira-
tory distress syndrome (ARDS) (venovenous ECMO)
[1,19,20]. Data on patients who received rFVIIa while
receiving ECMO were extracted and retrospectively ana-
lyzed. Patients who underwent ECMO during their ICU
stay but received rFVIIa before ECMO implantation or
after its removal were not included. The following data
were extracted from our computerized charts and
recorded: demographic characteristics at ICU admission;
ECMO type (venoarterial or venovenous), and reason
for implantation; bleeding site; blood products required
(number of units of packed red cells (PRCs), platelets
and fresh-frozen plasma (FFP); specific medical, surgical,
or interventional radiology hemostatic measures applied
to stop bleeding; and details regarding rFVIIa use (total
dose, number of infusions).
In our institution, rFVIIa use adheres to guidelines
recommending correction of coagulation parameters
(prothrombin time (PT) > 50%, activated partial throm-
boplastin time (aPTT) ratio < 2, platelets > 50,000/ml,
fibrinogen > 1 g/L), hypothermia (temperature > 36°C),
hypocalcemia (calcemia > 2.2 mM), and anemia (hemato-
crit > 24%) before its infusion (Figure 1). Substitution
limits for fibrinogen and platelets were 1 g/L and 50,000/
ml, respectively. Our institution protocol for rFVIIa
infusion is to give the patient an initial dose of 60 μg/kg,
followed by a second dose of 60 μg/kg if the physician
estimates that the bleeding does not stop. Factor XIII was
never given, and we also never use antifibrinolytic agents
such as tranexamic acid in such situations.
Number of blood products transfused (PRC, platelets,
FFP, cryoprecipitate) and volume of chest-tube output
(for patients with intrathoracic bleeding) were used to
quantify bleeding. Volumes were recorded from 24
hours before until 24 hours after rFVIIa administration.
In France, volumes of PRC, platelets, and FFP are 240
to 260 ml, 200 to 600 ml (depending on platelet concen-
tration), and 200 to 220 ml, respectively. rFVIIa efficacy
against bleeding was defined by its control (if visually in
circuits), the diminished need for blood-product transfu-
sion, and no early recurrence.
The following thrombotic complications were defined
as clinically relevant thrombotic episodes: ischemic
stroke or peripheral arterial embolism in patients with
venoarterial ECMO, pulmonary embolism for patients
on venovenous ECMO (suspected in the case of hemo-
dynamic instability, unexplained oxygenation decrease),
or circuit and/or oxygenator thrombosis for both
ECMO types (either a total thrombosis requiring urgent
changing of the circuit or partial thrombosis responsible
for hemolysis). Duration of mechanical ventilation, ICU
length of stay, and ICU mortality also were recorded.
This epidemiologic study did not require ethical
approval, in accordance with the ethical standards of
our institution’s Committee for the Protection of
Human Research Subjects (CCP Ile de France VI,
Groupe Hospitalier Pitié-Salpêtrière, Paris). In accor-
dance with French law, no informed consent was
obtained because this epidemiologic study did not mod-
ify existing diagnostic or therapeutic strategies.
ECMO circuit and implantation
The extracorporeal system consisted of polyvinyl chlor-
ide tubing, a membrane oxygenator (QuadroxBioline;
Jostra-Maquet, Orléans, France; or Eos ECMO, Sorin,
Milan, Italy), a centrifugal pump (Rotaflow, Jostra-
Maquet, or Revolution, Sorin), and drainage and reinfu-
sion cannulae (Biomedicus Carmeda, Medtronic, Bou-
logne-Billancourt, France, or Edwards Lifesciences,
Irvine, CA, USA). An oxygen-air blender (Sechrist
Industries, Anaheim, CA, USA) was used to ventilate
the membrane oxygenator [1].
Two types of venoarterial ECMO were used: periph-
eral (femorofemoral) or central. In patients with periph-
eral ECMO, arterial and venous femoral cannulae were
placed percutaneously or surgically. When the femoral
artery caliber was small or signs of leg ischemia
appeared, an additional 7Fr cannula was inserted distally
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into the femoral artery to prevent or treat severe leg
ischemia [1]. Patients with central ECMO had right
atrial drainage and aortic reinfusion cannulae.
For venovenous ECMO, two-site cannulation was used,
and all cannulae were inserted percutaneously. The drai-
nage cannula was inserted into the femoral vein (extend-
ing into the inferior vena cava), and the reinfusion
cannula was inserted into the internal jugular vein
(extending into the right atrium).
Patient management under ECMO
All patients were continuously infused with unfractioned
heparin to achieve an aPTT ratio < 1.5 for venovenous
ECMO and between 1.5 and 2 for venoarterial ECMO.
Figure 1 Local guidelines for recombinant activated factor VII (rFVIIa) use to control refractory hemorrhage in patients with
extracorporeal membrane oxygenation.
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No heparin bolus was injected at ECMO initiation. The
heparin dose was adapted at least once daily, according
the aPTT value and clinical tolerance; it was stopped
when bleeding occurred and restarted after bleeding was
controlled. The oxygenator membrane was changed
when fibrin deposition or thrombi had deleterious
effects on blood oxygenation, the platelets count
decreased significantly (< 50,000/ml), or hemolysis
appeared. The circuit was checked daily by experienced
perfusionists and changed when fibrin deposits or clots
accumulated on the membrane, hemolysis or thrombo-
penia was observed, or blood oxygenation declined shar-
ply, and systematically, every 8 to 10 days [1].
Statistical analyses
Gaussian variables are expressed as mean ± SD, and
non-gaussian variables, as medians (25th to 75th inter-
quartile range (IQR)). Continuous variables were com-
pared with the Student t test or the Mann-Whitney U
test, as appropriate. Categoric variables were compared
with the c2 test. All P values were two-tailed, and statis-
tical significance was defined as P < 0.05. Analyses were
performed by using StatView 5.0 (SAS Institute Inc.,




From January 2006 to March 2011, 315 of our ICU
patients underwent venoarterial ECMO and, 62, venove-
nous ECMO. Among these 377 patients, 15 (4%)
received rFVIIa while receiving ECMO. Four of them
were supported with venovenous ECMO, and 11, 10
with preexisting cardiac disease, with venoarterial
ECMO; their admission characteristics are listed in
Table 1. Two patients were immunocompromised: an
HIV-infected patient received venovenous ECMO, and
an allogenic stem-cell transplantation recipient had
venoarterial ECMO.
Bleeding episode
For 12 (80%) patients (11 with venoarterial and one with
venovenous ECMO), the source of bleeding was the sur-
gical site (that is, mediastinal bleeding (all had a sternot-
omy, either for cardiac surgery or central ECMO
cannulation)). The bleeding sources in the remaining
three patients with venovenous ECMO are listed in
Table 2. For all 15 patients, all medical and surgical
means to control bleeding were exhausted before rFVIIa
infusion: for the 12 patients with surgical sites, reinter-
ventions excluded curable causes of bleeding; a patient
with massive epistaxis received anterior and posterior
nasopharyngeal packing; another with hemothorax
required arterial embolization despite surgery because of
persistent bleeding; and the last had uterine polyp-
related hemorrhage treated with arterial embolization.
These measures failed to control bleeding, as attested to
by their transfusion requirements within the 24 hours
preceding rFVIIa. Before rFVIIa injection, hemostasis
parameters, body temperature, pH, and calcemia were
within acceptable ranges recommended by our guide-
lines and the manufacturer for rFVIIa infusion. All
patients received the same dosage for each rFVIIa infu-
sion according to our institution guidelines, without
protocol violation, (that is, a dose of 60 μg/kg for each
infusion). Ten patients received one rFVIIa infusion,
three received two, one required three, and the last was
given four. Patients received a median rFVIIa dose of 77
(54 to 144) μg/kg.
Table 1 Characteristics of the 15 patients
Characteristic Value
Male sex 10 (66.7)
Age (years) 47 (32-53)
SAPS II at admission 79 (62-90)
SOFA at admission 15 (10-17)
McCabe & Jackson comorbidity score 0 (0-1)
< 2 12 (80)
≥ 2 3
Reason for ECMO
Venoarterial ECMO 11 (73.3)
Postcardiotomy cardiogenic shock 5
Cardiac transplantation 1
Infarction-related cardiogenic shock 3
Myocarditis 2




Preexisting heart disease 10 (66.7)
Ischemic cardiomyopathy 4
Nonischemic dilated cardiomyopathy 2
Valvular cardiomyopathy 1
Hypertension-related cardiomyopathy 2
Congenital heart disease 1
Diabetes mellitus 1 (6.7)
Obesity (BMI > 30 kg/m-2) 3 (20)
30 < BMI < 35 2
35 < BMI < 40 1
BMI > 40 0
Immunocompromised 2 (13)
HIV infected 1
Allogenic stem-cell transplantation 1
Data are expressed as n (%) or median (IQR). ARDS, acute respiratory distress
syndrome; BMI, body mass index; ECMO, extracorporeal membrane
oxygenation; HIV, human immunodeficiency virus; SAPS, simplified acute
physiology score; SOFA, sequential organ-failure assessment.
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Bleeding control
For 14 patients, bleeding dramatically decreased after
rFVIIa infusion, as shown by the diminished need for
blood products. Compared with the 24-hour period
before rFVIIa infusion, RBC administration decreased a
median of 75% (56.5% to 81%], and FFP declined 84%
(67% to 100%) within the following 24 hours (P =
0.0008) (Figure 2). Moreover, for the 10 patients whose
blood loss could be quantified, chest-tube output
decreased from 2,057 (1,010 to 4,381) ml during the
24 hours before rFVIIa infusion to 850 (622 to 1,356]
ml during the 24 hours after (P = 0.008). The patient
whose bleeding persisted despite surgical intervention,
arterial embolization, and rFVIIa infusion, underwent
another surgical procedure; the surgeon found active
bleeding of an injured intercostal artery that was finally
controlled with vascular repair.
rFVIIa-related thrombotic events
No clinical signs of thrombosis were observed after
rFVIIa infusion. Two circuits in patients with venoar-
terial ECMO were changed within the 48 hours after
rFVIIa infusion because of fibrin deposits and related
hemolysis, but no massive circuit thrombosis occurred.
One patient progressed to brain death during the
24 hours after the infusion, and because no brain CT
scan was performed, an ischemic stroke could not be
ruled out.
Outcomes
The median durations of ECMO, mechanical ventilation,
and ICU stay were 13 (6 to 37), 45 (6 to 49], and 54 (6
to 55) days, respectively. Nine (60%) of the 15 patients
died, eight who had venoarterial ECMO; four developed
multiorgan failure 1 (0 to 2) days after and despite con-
trolling the hemorrhage; three patients died of septic
shock 21 (14 to 88) days after bleeding stopped; two
died of brain death within 24 hours after rFVIIa infu-
sion, one of a cerebral hemorrhage (the possibility of an
ischemic stroke with secondary conversion to a hemor-
rhagic stroke was ruled out by two experts, based on
CT scan), and the other of unknown etiology. The only
patient whose hemorrhage was not controlled by rFVIIa
had active bleeding of an injured intercostal artery that
was surgically repaired; he was discharged alive after >
100 days in the ICU.
Discussion
Herein, we describe our experience with rFVIIa for
refractory bleeding in 15 patients receiving ECMO. For
14 patients, bleeding dramatically decreased after rFVIIa
infusion without relapse. Although no massive thrombo-
tic events were observed in our patients, two ECMO cir-
cuits were changed during the 48 hours after rFVIIa
administration because of oxygenator clotting that may
have resulted from this procoagulant treatment. Those
circuits were changed 8 and 11 days after ECMO initia-
tion, which, in our experience, may be the normal life-
time of membranes. Moreover, one patient progressed
to brain death early after rFVIIa infusion, and because
ischemic stroke could not be excluded as its cause, a
thrombotic complication could not be ruled out. How-
ever, another explanation in this patient could be a cere-
bral hemorrhage as the cause of death. If so, and despite
the use of rFVIIa, the rate of cerebral hemorrhage in
this population would be very high (13%). Although
mortality was high, 40% of our patients with intractable
bleeding survived. As a comparison, the survival rate of
other ECMO patients (not having received rFVIIa) dur-
ing the same time period in our unit was 55% (differ-
ence not statistically significant) [21].
Table 2 Bleeding characteristics and treatments











Packed red blood cell 17 (13.5-19)
Fresh-frozen plasma 14 (9-21.5)
Concentrated platelets 5 (3-8)
Biologic parameters before and
after rFVIIa infusion
Before After
Hemoglobin 7.5 (7.1-8.6) 9 (8.2-9.8)
Platelets 83 (61-117) 68 (61-106)
PT 46 (42-52) 101 (54-120)
aPTT 1.7 (1.4-2.2) 1.4 (1.2-1.9)
Ionized calcemia 1.10 (1.05-1.20) 1.17 (1.03-1.28)
pH 7.37 (7.28-7.42) 7.41 (7.34-7.47)
Temperature before rFVIIa infusion (°C) 36.4 (34.3-37.1)
rFVIIa dose infused (μg/kg) 77 (54-144)






Data are expressed as number (%) or medians (IQR). aPTT, activated
thromboplastin time; ECMO, extracorporeal membrane oxygenation; PT,
prothrombin time; rFVIIA, recombinant factor VIIa.
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To the best of our knowledge, we report the largest
cohort of adult ECMO patients treated with rFVIIa. Sev-
eral reports are available in the literature, nine of them
focusing on pediatric patients (for a total of 48 infants)
and six on adults (for a total of 9 adults) [15-18,22-30]
(Table 3). All authors concurred about its control of
bleeding and decrease of blood-products requirements.
Some patients experienced circuit thromboses or oxyge-
nator failure, and eight had systemic thromboses or
emboli. Most events occurred in pediatric patients, and
another procoagulant treatment was given in some
cases. rFVIIa was given in doses ranging from 40 to 220
μg/kg. For the 26 patients for whom these data were
available, eight who experienced thrombotic events had
not received higher doses than had those without: 90
μg/kg (83 to 141) versus 192 μg/kg (93 to 252), respec-
tively (P = 0.46). In our patients, except for one patient
who progressed to brain death and in whom a major
stroke could not be ruled out, no major thrombotic epi-
sode occurred. However, we did not measure thrombo-
sis and fibrinolysis with thromboelastogram, D-dimer, or
other tests. We thus cannot exclude that in some
patients, the development of multiorgan failure may be
related to, or have been favored by microthrombosis of
end organs, and that this may have affected the mortal-
ity. Nevertheless, the lack of thrombotic complications
in our patients contrasts with the high rate quoted in
the literature. We can only speculate on the causes of
this difference. We do not think it could be related to
the dose of rFVIIa, because patients who experienced
thrombotic events in the literature had not received
higher doses than had ours. Interestingly, most throm-
botic episodes occurred in pediatric patients: of the 16
patients who experienced a major thrombotic event,
14 were infants (30% of this population), and only two
were adults (22% of this population). This higher rate in
pediatric patients may be explained by differences in cir-
cuit size and by differences of clotting system between
infants and adults.
Many possibilities could explain bleeding in ECMO
patients. First, surgeries before, after, or during ECMO
are potential sites of bleeding. Second, even with percu-
taneous cannulation, the insertion site is another poten-
tial source of bleeding [2]. Third, coagulation disorders
in patients on ECMO may be caused by heparin use,














p = .0008 

















Figure 2 Blood-product transfusions before and after recombinant activated factor VII (rFVIIa) infusion. Each line represents one patient.
Black lines, red blood cells; dashed gray line, fresh-frozen plasma, with respective medians [25th to 75th interquartile range] as □ and ○.
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oxygenator membrane and/or specific coagulation-factor
abnormalities. In addition to impaired platelet function,
patients receiving ECMO may develop acquired von
Willebrand syndrome [6]; shear stress during extracor-
poreal support is responsible for conformational
modifications of von Willebrand factor that becomes
exposed to metalloprotease-mediated cleavage [31]. The
resulting truncated von Willebrand factor no longer has
procoagulant activity [31]. A recent study by Heilmann
et al. [6] clearly demonstrated that patients with ECMO





















90-120 2 ↓81.9% PRC between before and after one
rFVIIa infusion






1 0.5 months 90 1 Bleeding stopped 1 (arterial) 1
Dominguez
et al. [24]
2 11 and 13
years
90 3 and 10 ↓88.7% total blood products between 12 hours
before and after rFVIIa infusion for case 1
↓46.7% total blood products between 24 hours








3 (2-3.5) ↓23.1% PRC between before and after one
rFVIIa infusion





11a 9.5 days 36.5 ±
18.2
1.6 ± 7 ↓42% PRC between before and after one rFVIIa
infusion (P < 0.05)
↓59.3% FFP between before and after one











1 5 days 70 2 ↓66.7% PRC after the two rFVIIa doses











2 (1.75-2) ↓46.5% (-71.25 to -2.25) PRC between 12 hours
before and after rFVIIa infusion
14.5% (-49.5 to 21.5) FFP between 24 hours



















1 56 years 146.5 2 ↓53.8% PRC between the 12 hours before and
after rFVIIa infusion
















2 (1-2) ↓61% (-79 to -47) PRC between the 12 hours
before and after rFVIIa infusion
↓33% (-58 to 42) FFP between the 24 hours









1 63 years 47 1 Bleeding stopped (↓90% bleeding after rFVIIa
infusion)
0 0
FFP, fresh-frozen plasma; PRC, packed red cells; rFVIIa, recombinant activated factor VII. aAnalysis concerns 11 of the 12 patients on ECMO who received rFVIIa;
one patient did not respond to rFVIIa. bThe authors reported on 12 patients, among whom four were infants with ECMO, five were adults with ECMO, and three
were adults with ventricle-assist devices.
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developed acquired von Willebrand syndrome, whereas
patients without any such support did not. Because of
these coagulation disorders, the coagulation system
should be closely monitored in patients with ECMO, to
avoid bleeding but also thrombotic complications.
Logan et al. [32] recently evaluated off-label rFVIIa
use in patients with intractable bleeding (2000 to 2008)
and found that, in US hospitals, its use increased > 140-
fold, so that in 2008, 97% of in-hospital administrations
were off-label. Moreover, Yank et al. [14] evaluated the
benefits and disadvantages of rFVIIa use for five off-
label indications: intracranial hemorrhage, cardiac sur-
gery, trauma, liver transplantation, and prostatectomy.
They reported that, for intracranial hemorrhage, survival
was not improved with rFVIIa use across a range of
doses, but the arterial embolism rate increased; cardiac
surgery-associated mortality was unchanged, but risk of
thromboembolism was increased; and posttrauma mor-
tality and thromboembolism rates were unaffected, but
the ARDS risk was lower. Primary clotting disorders
represented roughly 5% of off-label rFVIIa use in this
recent analysis [14]. rFVIIa is an effective agent to treat
refractory bleeding in von Willebrand disease patients
and to treat or prevent bleeding in patients with alloan-
tibodies or autoantibodies directed against von Willeb-
rand factor [33]. According to a recent review, the
positive response rate was 96%, with a low frequency of
adverse events (only one case of myocardial infarction
in a patient with type 2A von Willebrand disease) [34].
However, major thrombotic events can occur [35].
Thus, rFVIIa might be a potential therapeutic option for
patients receiving ECMO with intractable bleeding
despite conventional treatment (including normalization
of coagulation parameters, surgery, and embolization),
but clinicians must be aware of possible life-threatening
systemic thrombosis, emboli, or circuit clotting.
Our study has several limitations. First, although it is
the largest study to date, it is a small single-center
study. However, the number of reported patients who
received rFVIIa remains relatively low.
Second, because of its retrospective design, our study
carries the inherent bias of this type of study. For exam-
ple, bleeding control could be the natural evolution of
the refractory bleeding episode due to coagulation opti-
mization and/or interventional treatment rather than
true rFVIIa efficacy. Nevertheless, our data on dimin-
ished blood-product needs and chest-drainage output
clearly support rFVIIa efficacy, in agreement with the
available literature.
Third, our study lacks a control group. Having a con-
trol group of ECMO patients with intractable bleeding
but not treated with rFVIIa might have helped to deter-
mine whether the outcome would have been better with
rFVIIa. However, because this disease is not frequent
and because all patients with intractable bleeding
received rFVIIa, this comparison is not possible.
Fourth, except for standard coagulation tests like
aPTT or PT, we did not explore coagulation abnormal-
ities more extensively, particularly in light of the recent
description of acquired von Willebrand syndrome.
Moreover, we did not measure von Willebrand antigen,
ristocetin-cofactor activity, and collagen-binding capa-
city, known to be decreased in ECMO patients [6].
Fifth, rFVIIa use in ECMO patients remains off-label.
Because of the scarcity of such cases, a randomized
study to evaluate rFVIIa benefit in patients with persis-
tent bleeding under ECMO is excluded. Although it
seems, based on our patients and the literature, that
rFVIIa may be useful in ECMO patients to stop bleed-
ing, whether its use decreases mortality rate in this par-
ticular setting remains to be determined.
Last, because of our population, the results presented
here apply mostly to bleeding in the setting of venoar-
terial ECMO and to surgical-site bleeding.
Conclusions
In our experience, rFVIIa use for patients with ECMO
with intractable bleeding was associated with bleeding
control and decreased blood-product requirements.
Except one patient who progressed to brain death and
in whom a major stroke could not be ruled out, no
major thrombotic episode occurred, but such events
have been reported, mostly in pediatric patients, with-
out any dose/effect relation. Despite a high mortality,
40% of our patients survived, similar to the previously
published rate [15-18,22-30], and without statistical dif-
ference as compared with the 55% survival rate of our
ECMO patients who did not receive rFVIIa. Therefore,
we conclude that rFVIIa may be used to control refrac-
tory bleeding in patients receiving ECMO. However, its
use should be considered, and clinicians should be
aware of the risk of potentially life-threatening systemic
thrombosis, emboli, or circuit clotting. Whether
rFVIIa use in such patients may save lives remains to
be determined.
Key messages
• rFVIIa may be used to control intractable bleeding
in ECMO patients.
• Before its use, clinicians should exhaust all medical
and surgical means to control bleeding.
• Clinicians should be aware of the risk of major
thrombotic events after rFVIIa.
• Whether rFVIIa may save lives in this population
has not been determined.
• The coagulation system should be closely moni-
tored in patients with ECMO to avoid bleeding and
thrombotic complications.
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